Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on α1‐adrenoceptor antagonists
Open Access
- 4 May 2005
- journal article
- review article
- Published by Wiley in BJU International
- Vol. 95 (s4), 29-36
- https://doi.org/10.1111/j.1464-410x.2005.05485.x
Abstract
An update of a systematic review of α1‐adrenoceptor (AR) antagonists in the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) showed that these agents have comparable efficacy. The total symptom score is improved by 30–45% and maximum urinary flow rate by 15–30% vs baseline. α1‐AR antagonists that can be started at their therapeutic dose have a more rapid onset of action than α1‐AR antagonists that have to be titrated. α1‐AR antagonists can be differentiated according to their tolerability. Alfuzosin (especially the 10 mg once daily dose) and tamsulosin (especially the 0.4 mg once daily dose) are better tolerated than doxazosin and terazosin. However, alfuzosin might induce more cardiovascular adverse events (AEs) in the elderly and/or patients with cardiovascular comorbidity and/or comedication. Tamsulosin tends to interfere less with blood pressure regulation and induce less vasodilatory AEs than alfuzosin, especially in the elderly, and is well tolerated in patients with cardiovascular comorbidity and/or comedication. Cardiovascular AEs might lead to potentially serious complications such as falls, fractures and institutionalization. Abnormal ejaculation has mainly been reported in placebo‐controlled trials with tamsulosin but in direct comparative trials its rate with tamsulosin 0.4 mg was similar to, or only slightly higher than, the rate with alfuzosin. In addition, abnormal ejaculation is not reported as bothersome by the patient or associated with serious complications. It can be concluded that an α1‐AR antagonist with a low potential to interfere with blood pressure regulation and to induce cardiovascular AEs, also in patients with cardiovascular comorbidity and/or comedication, can be considered a first‐choice treatment option in LUTS/BPH.Keywords
This publication has 56 references indexed in Scilit:
- Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in relation to the patient's risk profile for progressionBJU International, 2005
- Management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the central role of the patient risk profileBJU International, 2005
- Ejaculatory dysfunction and alpha1-adrenoceptor antagonistsBJU International, 2004
- Long-Term Safety and Efficacy of a Once-Daily Formulation of Alfuzosin 10 mg in Patients with Symptomatic Benign Prostatic Hyperplasia: Open-Label Extension StudyEuropean Urology, 2002
- Review of Orthostatic Tests on the Safety of Tamsulosin, a Selective α1A-Adrenergic Receptor Antagonist, Shows Lack of Orthostatic Hypotensive EffectsJournal of International Medical Research, 2001
- Efficacy and Safety of a New Prolonged Release Formulation of Alfuzosin 10 mg Once Daily versus Alfuzosin 2.5 mg Thrice Daily and Placebo in Patients with Symptomatic Benign Prostatic HyperplasiaEuropean Urology, 2000
- A SECOND PHASE III MULTICENTER PLACEBO CONTROLLED STUDY OF 2 DOSAGES OF MODIFIED RELEASE TAMSULOSIN IN PATIENTS WITH SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIAJournal of Urology, 1998
- Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia)British Journal of Urology, 1997
- Tamsulosin, a selective α1c‐adrenoceptor* antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH)British Journal of Urology, 1995
- Doxazosin Treatment in Patients with Prostatic ObstructionScandinavian Journal of Urology and Nephrology, 1993